. 2018 Jul 25;62:10.29219/fnr.v62.1398. doi: 10.29219/fnr.v62.1398

Table 3.

Effects of pretreatment with FPLR on the levels of liver SOD, CAT, GSH, and MDA in CCl₄-treated mice ( $\bar{X}$ ± SD, n = 10)

Groups	SOD (U/mg prot)	CAT (U/mg prot)	GSH (mg/g prot)	MDA (nmol/mg prot)
Normal control	59.84 ± 5.98^a	38.55 ± 2.78^a	4.65 ± 0.73^a	1.92 ± 0.52^d
CCl₄-treated	45.11 ± 4.22^d	20.84 ± 2.14^d	1.97 ± 0.48^c	3.99 ± 0.93^a
Bifendate (100 mg/kg bw) + CCl₄	55.04 ± 5.27^ab	32.35 ± 2.55^b	4.20 ± 0.45^ab	2.47 ± 0.39^cd
FPLR (50 mg/kg bw) + CCl₄	48.11 ± 2.36^cd	26.95 ± 1.36^c	3.56 ± 0.73^b	3.32 ± 0.64^b
FPLR (100 mg/kg bw) + CCl₄	51.14 ± 4.46^bcd	28.89 ± 2.24^bc	3.88 ± 0.79^b	2.86 ± 0.78^bc
FPLR (200 mg/kg bw) + CCl₄	53.21 ± 3.66^bc	31.92 ± 4.61^b	4.08 ± 0.73^ab	3.16 ± 0.51^b

Data are shown as mean values ± SD for the 10 mice in each group. Values within a column with different letters indicate significant difference among different groups at p < 0.05.